Plain-English translation of NCT07024160 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage safety trial of , a new medication designed to reverse the effects of certain blood-thinning drugs. Researchers are giving healthy volunteers a single dose of (or a placebo) to see how safe it is, how the body processes it, and how it works in the body. The goal is to eventually help patients who are taking anticoagulant medications and need their blood-thinning effects reversed quickly.
Blood-thinning medications like rivaroxaban and apixaban are commonly prescribed to prevent blood clots, but sometimes patients need those effects reversed—for example, before emergency surgery or after an overdose. This medication is being developed as a potential reversal agent to meet that critical medical need.
You likely qualify if…
You likely don't qualify if…
You will visit the research center to receive a single injection of either or a placebo (a fake treatment). Researchers will then monitor you closely to measure how safe the medication is, how your body processes it, and what effects it has on your blood clotting system. The study involves 40 healthy volunteers divided into five groups, each receiving a different dose, so researchers can determine the safest dose to use.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
China